1-2 of 2
Yandong Shen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary A. Anderson
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1439–1443.
https://doi.org/10.1182/bloodadvances.2023011327
Published: 2024
Includes: Supplemental data
Journal Articles

IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment

Yandong Shen, Kyle Crassini, Narjis Fatima, Michael O’Dwyer, Michael O’Neill, Richard I. Christopherson, Stephen P. Mulligan, O. Giles Best
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5093–5106.
https://doi.org/10.1182/bloodadvances.2019001369
Published: 2020
Includes: Supplemental data